董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Lindsay Wakefield | 男 | Independent Non-Executive Director | 66 | 7.49万 | 941.81 | 2024-09-30 |
| Jerzy Muchnicki | 男 | Non-Independent Non-Executive Director | 68 | 8.74万 | 26308.59 | 2024-09-30 |
| Peter Rubinstein | 男 | Chairman of the Board | 58 | 15.02万 | 30813.20 | 2024-09-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Carl Stubbings | 男 | Chief Commercial Officer | 69 | 30.17万 | 未持股 | 2024-09-30 |
| Simon Morriss | 男 | Chief Executive Officer | 51 | 44.96万 | 未持股 | 2024-09-30 |
| Kevin Camilleri | 男 | Chief Executive Officer, Easy DNA | 47 | 29.61万 | 未持股 | 2024-09-30 |
| Mark Ziirsen | 男 | Company Secretary / Chief Financial Officer | 61 | 未披露 | 未持股 | 2024-09-30 |
董事简历
中英对照 | 中文 | 英文- Lindsay Wakefield
-
Lindsay Wakefield于2014年9月24日被任命为董事。Wakefield博士于1985年设立Safetech。他于1993年离开Medicine，担任该公司的全职首席执行官。接下来的25年里，Safetech成为澳大利亚材料处理与起重设备市场的一支力量，设计并制造范围广泛的工业产品。Safetech于2006年被授予“ Telstra Australian National Business of the Year”。Safetech于2013年合并为STS Safetech Tieman Solutions，该公司是澳大利亚最大的船坞设备、货物起重机与海关起重解决方案的制造商与供应商。
Lindsay Wakefield,was appointed to the Board on September 24, 2014. He started Safetech Pty Ltd in 1985 and over the next 25 years, Safetech became a force in the Australian material handling and lifting equipment market, designing and manufacturing a wide range of industrial products. In 1993, he left medicine to become the full-time CEO of Safetech. In 2006, Safetech was awarded the Telstra Australian National Business of the Year. In 2013, Safetech merged and ultimately acquired Tiemen Materials Handling.Dr Wakefield continues as the CEO of Safetech. It is Australia's largest manufacturer and supplier of dock equipment, freight hoists and custom lifting solutions. Safetech employs approximately 100 people. Dr Wakefield has been a biotech investor for more than 20 years. - Lindsay Wakefield于2014年9月24日被任命为董事。Wakefield博士于1985年设立Safetech。他于1993年离开Medicine，担任该公司的全职首席执行官。接下来的25年里，Safetech成为澳大利亚材料处理与起重设备市场的一支力量，设计并制造范围广泛的工业产品。Safetech于2006年被授予“ Telstra Australian National Business of the Year”。Safetech于2013年合并为STS Safetech Tieman Solutions，该公司是澳大利亚最大的船坞设备、货物起重机与海关起重解决方案的制造商与供应商。
- Lindsay Wakefield,was appointed to the Board on September 24, 2014. He started Safetech Pty Ltd in 1985 and over the next 25 years, Safetech became a force in the Australian material handling and lifting equipment market, designing and manufacturing a wide range of industrial products. In 1993, he left medicine to become the full-time CEO of Safetech. In 2006, Safetech was awarded the Telstra Australian National Business of the Year. In 2013, Safetech merged and ultimately acquired Tiemen Materials Handling.Dr Wakefield continues as the CEO of Safetech. It is Australia's largest manufacturer and supplier of dock equipment, freight hoists and custom lifting solutions. Safetech employs approximately 100 people. Dr Wakefield has been a biotech investor for more than 20 years.
- Jerzy Muchnicki
-
Jerzy Muchnicki于2018年1月31日被任命为董事会成员，并于2019年9月24日被任命为临时首席执行官。被任命为临时首席执行官之前，他曾担任公司的兼职业务开发董事。Muchnicki博士毕业于莫纳什大学（Monash University），担任私人执业职位约25年，担任墨尔本大学（Melbourne University）的学生健康主管。在过去的14年里，他主要参与从基因沉默到再生医学的生物技术领域的商业化和资助研发。他是Speed Panel Holdings（火灾额定和声学墙解决方案的世界领导者）的联合创始人兼非执行董事。他也是CandleBets公司（软件开发公司，正在为游戏行业创建区块链赋能平台）的联席创始人。
Jerzy Muchnicki,was appointed to the Board on January 31, 2018 and acted as Interim Chief Executive Officer from September 2019 till the appointment of Mr. Simon Morriss to the role. Dr. Muchnicki graduated from Monash University and has held positions in private practice for over 25 years and was Head of Student Health at The University of Melbourne. For the past 14 years, he has been involved in commercialization and funding R&D in the biotechnology sector from gene silencing to regenerative medicine.Dr. Muchnicki brings with him strong commercial and medical skills, including broad interests in software development, blockchain and sustainable building materials. He is a co-founder and Non-Executive Director of Speed Panel Holdings a world leader in fire rated and acoustic wall solutions. He is also the co-founder of Candlebets, a software development company that is creating blockchain enabled platforms for the gaming industry. - Jerzy Muchnicki于2018年1月31日被任命为董事会成员，并于2019年9月24日被任命为临时首席执行官。被任命为临时首席执行官之前，他曾担任公司的兼职业务开发董事。Muchnicki博士毕业于莫纳什大学（Monash University），担任私人执业职位约25年，担任墨尔本大学（Melbourne University）的学生健康主管。在过去的14年里，他主要参与从基因沉默到再生医学的生物技术领域的商业化和资助研发。他是Speed Panel Holdings（火灾额定和声学墙解决方案的世界领导者）的联合创始人兼非执行董事。他也是CandleBets公司（软件开发公司，正在为游戏行业创建区块链赋能平台）的联席创始人。
- Jerzy Muchnicki,was appointed to the Board on January 31, 2018 and acted as Interim Chief Executive Officer from September 2019 till the appointment of Mr. Simon Morriss to the role. Dr. Muchnicki graduated from Monash University and has held positions in private practice for over 25 years and was Head of Student Health at The University of Melbourne. For the past 14 years, he has been involved in commercialization and funding R&D in the biotechnology sector from gene silencing to regenerative medicine.Dr. Muchnicki brings with him strong commercial and medical skills, including broad interests in software development, blockchain and sustainable building materials. He is a co-founder and Non-Executive Director of Speed Panel Holdings a world leader in fire rated and acoustic wall solutions. He is also the co-founder of Candlebets, a software development company that is creating blockchain enabled platforms for the gaming industry.
- Peter Rubinstein
-
Peter Rubinstein于2018年1月31日被任命为董事会成员。他在从早期技术商业化到在澳大利亚证券交易所上市的早期阶段有超过20年的经验。他是一名律师，在搬到Montech（Monash University的商业分支）之前曾在一家大型国家公司工作。Rubinstein先生在生物技术，数字支付和可再生能源等多个领域的技术公司的创建，推出和管理方面有着丰富的经验。Rubinstein先生也是DigitalX Limited DCC的董事。
Peter Rubinstein,was appointed to the Board on January 31, 2018 and appointed as Chairman in April 2020. He has over 20 years' experience in early-stage technology commercialization through to public listings on the ASX. He is a lawyer, having worked at a large national firm prior to moving in-house at Montech, the commercial arm of Monash University.Mr. Rubinstein has had significant exposure to the creation, launch and management of a diverse range of technology companies in biotech, digital payments and renewable energy. Mr. Rubinstein is also a Non-Executive Director of DigitalX Limited (ASX: DCC). - Peter Rubinstein于2018年1月31日被任命为董事会成员。他在从早期技术商业化到在澳大利亚证券交易所上市的早期阶段有超过20年的经验。他是一名律师，在搬到Montech（Monash University的商业分支）之前曾在一家大型国家公司工作。Rubinstein先生在生物技术，数字支付和可再生能源等多个领域的技术公司的创建，推出和管理方面有着丰富的经验。Rubinstein先生也是DigitalX Limited DCC的董事。
- Peter Rubinstein,was appointed to the Board on January 31, 2018 and appointed as Chairman in April 2020. He has over 20 years' experience in early-stage technology commercialization through to public listings on the ASX. He is a lawyer, having worked at a large national firm prior to moving in-house at Montech, the commercial arm of Monash University.Mr. Rubinstein has had significant exposure to the creation, launch and management of a diverse range of technology companies in biotech, digital payments and renewable energy. Mr. Rubinstein is also a Non-Executive Director of DigitalX Limited (ASX: DCC).
高管简历
中英对照 | 中文 | 英文- Carl Stubbings
Carl Stubbings自2012年7月起担任公司的业务总监。在加入公司之前，Stubbings先生是Focus Diagnostics股份有限公司（Focus Diagnostics, Inc.，Quest Diagnostics 股份有限公司（Quest Diagnostics Inc.）子公司）的销售和营销副总裁（2008年2月-2012年6月）。
Carl Stubbings,joined the Company in 2021 and was appointed as Chief Commercial Officer on September 1, 2021. Mr Stubbings is an experienced senior leader in the biotechnology and diagnostics industry with a focus on commercialization, sales, marketing and business development.He has considerable experience commercializing diagnostic products, both locally and globally. Based in the USA for 13 years, he served as Senior Vice President for Panbio USA Ltd and Vice-President of Sales and Marketing for Focus Diagnostics, a subsidiary of Quest Diagnostics (NASDAQ:DGX), one of the world's largest pathology laboratories.In July 2012, Mr Stubbings moved back to Australia where he was appointed Chief Business Officer at Benitec Biopharma Limited (ASX: BLT, NASDAQ: BNTC). More recently he has assisted several Australian biotech companies with their commercialization strategies. These companies include BCAL Diagnostics, a start-up company developing a blood test for breast cancer, Minomic, an Immuno Oncology company with a test for prostate cancer, and Biotron (ASX: BIT), a listed company that is developing and commercializing anti-viral small molecule therapies. In 2019 Mr Stubbings was appointed CEO and Managing Director of Sienna Cancer Diagnostics Ltd (ASX: SDX). In that role, he helped lead the successful merger between Sienna and BARD1 Life Sciences (ASX:BD1). Following the merger, Mr Stubbings was appointed Chief Operating Officer of the merged entity BARD1 Life Sciences.Mr Stubbings has a Bachelor of Applied Science (Medical Technology) from the Queensland University of Technology.- Carl Stubbings自2012年7月起担任公司的业务总监。在加入公司之前，Stubbings先生是Focus Diagnostics股份有限公司（Focus Diagnostics, Inc.，Quest Diagnostics 股份有限公司（Quest Diagnostics Inc.）子公司）的销售和营销副总裁（2008年2月-2012年6月）。
- Carl Stubbings,joined the Company in 2021 and was appointed as Chief Commercial Officer on September 1, 2021. Mr Stubbings is an experienced senior leader in the biotechnology and diagnostics industry with a focus on commercialization, sales, marketing and business development.He has considerable experience commercializing diagnostic products, both locally and globally. Based in the USA for 13 years, he served as Senior Vice President for Panbio USA Ltd and Vice-President of Sales and Marketing for Focus Diagnostics, a subsidiary of Quest Diagnostics (NASDAQ:DGX), one of the world's largest pathology laboratories.In July 2012, Mr Stubbings moved back to Australia where he was appointed Chief Business Officer at Benitec Biopharma Limited (ASX: BLT, NASDAQ: BNTC). More recently he has assisted several Australian biotech companies with their commercialization strategies. These companies include BCAL Diagnostics, a start-up company developing a blood test for breast cancer, Minomic, an Immuno Oncology company with a test for prostate cancer, and Biotron (ASX: BIT), a listed company that is developing and commercializing anti-viral small molecule therapies. In 2019 Mr Stubbings was appointed CEO and Managing Director of Sienna Cancer Diagnostics Ltd (ASX: SDX). In that role, he helped lead the successful merger between Sienna and BARD1 Life Sciences (ASX:BD1). Following the merger, Mr Stubbings was appointed Chief Operating Officer of the merged entity BARD1 Life Sciences.Mr Stubbings has a Bachelor of Applied Science (Medical Technology) from the Queensland University of Technology.
- Simon Morriss
Simon Morriss于2021年2月1日被任命为首席执行官，在制药、医疗保健和快速消费品行业拥有超过20年的经验，曾在赛诺菲和Blackmores担任高级管理职位。他在管理团队和成功执行跨销售、营销和品牌建设方面带来了丰富的经验。
Simon Morriss,was appointed as Chief Executive Officer on February 1, 2021 and brings over 20 years' experience within the Pharmaceutical, Healthcare and FMCG industries having held senior executive positions at Sanofi and Blackmores. He brings a wealth of experience in managing teams and successfully executing across sales, marketing and brand building.Additionally, Mr. Morriss has been critical in leading commercialization across these industries and understands the unique pressures and opportunities. He has led companies through strategic adaptation to execution and will be driving Genetic Technologies commercialization strategy and continue to drive innovation across the business.- Simon Morriss于2021年2月1日被任命为首席执行官，在制药、医疗保健和快速消费品行业拥有超过20年的经验，曾在赛诺菲和Blackmores担任高级管理职位。他在管理团队和成功执行跨销售、营销和品牌建设方面带来了丰富的经验。
- Simon Morriss,was appointed as Chief Executive Officer on February 1, 2021 and brings over 20 years' experience within the Pharmaceutical, Healthcare and FMCG industries having held senior executive positions at Sanofi and Blackmores. He brings a wealth of experience in managing teams and successfully executing across sales, marketing and brand building.Additionally, Mr. Morriss has been critical in leading commercialization across these industries and understands the unique pressures and opportunities. He has led companies through strategic adaptation to execution and will be driving Genetic Technologies commercialization strategy and continue to drive innovation across the business.
- Kevin Camilleri
Kevin Camilleri于2021年加入公司，并于2021年8月被任命为EasyDNA的首席执行官。他于2001年成为EasyDNA品牌的创始人。
Kevin Camilleri,joined the Company in 2021 and was appointed as Chief Executive Officer of EasyDNA on August 16, 2021. He was founder member of the EasyDNA brand in 2001 and grew the business over time into a leading international online provider of genetic testing services. A business graduate from the University of Bath in the UK, Mr. Camilleri has over the years accumulated a broad range of skills covering most aspects of business management including strategic, financial, organizational, operational and commercial skills. He brings to the company the ability to manage a cross-border organization in line with Genetic Technologies strategy for international expansion.- Kevin Camilleri于2021年加入公司，并于2021年8月被任命为EasyDNA的首席执行官。他于2001年成为EasyDNA品牌的创始人。
- Kevin Camilleri,joined the Company in 2021 and was appointed as Chief Executive Officer of EasyDNA on August 16, 2021. He was founder member of the EasyDNA brand in 2001 and grew the business over time into a leading international online provider of genetic testing services. A business graduate from the University of Bath in the UK, Mr. Camilleri has over the years accumulated a broad range of skills covering most aspects of business management including strategic, financial, organizational, operational and commercial skills. He brings to the company the ability to manage a cross-border organization in line with Genetic Technologies strategy for international expansion.
- Mark Ziirsen
Mark Ziirsen，于2024年7月16日被任命为首席财务官和公司秘书。Ziirsen先生拥有昆士兰大学商学学士学位、新英格兰大学MBA学位、澳洲会计师公会会员和澳大利亚公司董事协会成员。Mark是一位经验丰富的ASX和纳斯达克上市公司首席财务官、公司秘书和非执行董事。他的高管生涯跨越生命科学、技术和消费者领域，包括在Cochlear、Aristocrat、可口可乐 Amatil和Goodman Fielder等主要ASX上市公司担任高级财务领导职务。他曾在ASX上市公司担任非执行董事，包括担任审计委员会主席和主席，曾任职于Opyl Limited（ASX：OPL），一家在ASX上市的人工智能技术企业，专注于生命科学；Respiri Limited（ASX：RSH），一家易康 SaaS公司；Orcoda Limited（ASX：ODA），一家基于SaaS的技术公司。马克的职业生涯始于安永，从事商业咨询、税务和管理咨询工作。他最近担任的行政职务包括，执行主席Opyl Limited，Cenntro Electric集团（丨ASX：WWG）、Wiseway Group Limited（TERM3：WWG）、Anteris Technologies Limited（ASX：AVR）的首席财务官兼公司秘书，以及Cochlear（ASX：COH）的亚太区财务和IT总监。
Mark Ziirsen,was appointed as Chief Financial Officer and Company Secretary on July 16, 2024. Mr. Ziirsen holds an Bachelor of Commerce from University of Queensland, an MBA from University of New England, is a Fellow of CPA Australia and a member of Australian Institute of Company Directors. Mark is a highly experience ASX and Nasdaq listed CFO, Company Secretary and non-executive director. His executive career spans life science, technology and consumer and includes senior finance leadership roles with major ASX listed companies such as Cochlear, Aristocrat, Coca-Cola Amatil and Goodman Fielder. He has served a non-executive director of ASX listed companies, including roles as Chair and Chair of Audit Committees, for Opyl Limited (ASX:OPL), an ASX listed AI technology business focused on life sciences, Respiri Limited (ASX:RSH), an eHealth SaaS company, Orcoda Limited (ASX:ODA), a SaaS based technology company. Mark commenced his career with EY, working in business advisory, tax and management consulting. His most recent executive roles include, Executive Chair Opyl Limited, CFO and Company Secretary of Cenntro Electric Group (Nasdaq CENN), Wiseway Group Limited (ASX:WWG), Anteris Technologies Limited (ASX:AVR) and Director of Finance and IT for Asia Pacific at Cochlear (ASX:COH).- Mark Ziirsen，于2024年7月16日被任命为首席财务官和公司秘书。Ziirsen先生拥有昆士兰大学商学学士学位、新英格兰大学MBA学位、澳洲会计师公会会员和澳大利亚公司董事协会成员。Mark是一位经验丰富的ASX和纳斯达克上市公司首席财务官、公司秘书和非执行董事。他的高管生涯跨越生命科学、技术和消费者领域，包括在Cochlear、Aristocrat、可口可乐 Amatil和Goodman Fielder等主要ASX上市公司担任高级财务领导职务。他曾在ASX上市公司担任非执行董事，包括担任审计委员会主席和主席，曾任职于Opyl Limited（ASX：OPL），一家在ASX上市的人工智能技术企业，专注于生命科学；Respiri Limited（ASX：RSH），一家易康 SaaS公司；Orcoda Limited（ASX：ODA），一家基于SaaS的技术公司。马克的职业生涯始于安永，从事商业咨询、税务和管理咨询工作。他最近担任的行政职务包括，执行主席Opyl Limited，Cenntro Electric集团（丨ASX：WWG）、Wiseway Group Limited（TERM3：WWG）、Anteris Technologies Limited（ASX：AVR）的首席财务官兼公司秘书，以及Cochlear（ASX：COH）的亚太区财务和IT总监。
- Mark Ziirsen,was appointed as Chief Financial Officer and Company Secretary on July 16, 2024. Mr. Ziirsen holds an Bachelor of Commerce from University of Queensland, an MBA from University of New England, is a Fellow of CPA Australia and a member of Australian Institute of Company Directors. Mark is a highly experience ASX and Nasdaq listed CFO, Company Secretary and non-executive director. His executive career spans life science, technology and consumer and includes senior finance leadership roles with major ASX listed companies such as Cochlear, Aristocrat, Coca-Cola Amatil and Goodman Fielder. He has served a non-executive director of ASX listed companies, including roles as Chair and Chair of Audit Committees, for Opyl Limited (ASX:OPL), an ASX listed AI technology business focused on life sciences, Respiri Limited (ASX:RSH), an eHealth SaaS company, Orcoda Limited (ASX:ODA), a SaaS based technology company. Mark commenced his career with EY, working in business advisory, tax and management consulting. His most recent executive roles include, Executive Chair Opyl Limited, CFO and Company Secretary of Cenntro Electric Group (Nasdaq CENN), Wiseway Group Limited (ASX:WWG), Anteris Technologies Limited (ASX:AVR) and Director of Finance and IT for Asia Pacific at Cochlear (ASX:COH).